Conatus Pharmaceuticals Inc. buy stratec
Start price
02.03.18
/
50%
€49.43
Target price
04.03.19
€81.18
Performance (%)
-61.31%
End price
04.03.19
€19.12
Summary
This prediction ended on 04.03.19 with a price of €19.12. The BUY prediction by stratec for Conatus Pharmaceuticals Inc. performed very badly with a performance of -61.31%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Conatus Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -5.630% | -5.765% | 8.425% | 8.571% |
| iShares Nasdaq 100 | -8.559% | -13.005% | 17.297% | 28.853% |
| iShares Nikkei 225® | -9.576% | -9.058% | 3.827% | 0.117% |
| iShares S&P 500 | -6.631% | -7.103% | 17.407% | 31.169% |
Comments by stratec for this prediction
In the thread Conatus Pharmaceuticals Inc. diskutieren
Conatus, one of the most promising small cap NASH companies.
Conatus Pharmaceuticals (NASDAQ:CNAT) initiated with Outperform rating and $16 (208% upside) price target at Oppenheimer.
Conatus’s lead product candidate is emricasan, a first-in-class pan-caspase protease inhibitor designed to reduce the activity of human caspases. NASH has been associated with caspase activation. By reducing the activity of caspase, emricasan can potentially interrupt liver disease progression. And there is some compelling pre-clinical and clinical data to back this. Emricasan has already been studied in sixteen clinical trials and has shown promise. This was the reason Novartis entered into a collaboration agreement with Conatus in December 2016.
(Laufzeit überschritten)